BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET
Jason Matuszewski, Chairman and CEO, to present BioStem’s current position in the chronic wound care market and key opportunities for growth
POMPANO BEACH, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chairman and CEO, will present at the on Tuesday, July 15 at 2:00 ET. The presentation will take place at the Courtyard Boston Downtown, and management will be available for investor meetings throughout the day.
Presentation Details:
- Title: Invest in the Future of Advanced Wound Care with BioStem Technologies
- Summary: Join Jason Matuszewski for an introduction to BioStem Technologies, a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived biologics for advanced wound care. BioStem is focused on driving continued growth in its core allograft business while pursuing opportunities to expand its portfolio across the continuum of care, further strengthening its position in the wound care market.
- Date: July 15, 2025
- Time: 2:00 PM ET
- One-on-One Availability: For conference attendees wishing to schedule a meeting, please contact Noah Agron, VP Corporate Finance and Strategy, at .
About the Advanced Wound Care Summit
The Advanced Wound Care Summit is taking place July 15–17 and will bring together global leaders in wound care innovation, clinical research, and advanced therapeutics to address unmet needs in chronic wound management. With a focus on accelerating product development and enhancing patient outcomes, the summit will feature keynote presentations, interactive panels, and strategic networking opportunities.
The event is organized by Kisaco Research, a global leader in industry-specific events that connect business leaders and innovators to accelerate progress and commercialization across healthcare, biotech, and life sciences.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for advanced wound care. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure.
BioStem’s quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (“AATB”) and adhere to Good Tissue Practices (cGTP and Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion and American Amnion AC. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit .
Join BioStem’s Distribution List & Social Media:
To stay informed on the latest developments, sign-up for the Company’s email distribution list , and follow us on and .
Contact BioStem Technologies, Inc.:
Phone: 954-380-8342
Website:
E-Mail:
X:
Facebook:
Investor Relations:
Adam Holdsworth
E-Mail:
Phone: 917-497-9287
Note Regarding Forward-Looking Statements:
Except for statements of historical fact, this press release also contains forward-looking statements. These forward-looking statements relate to expectations or forecasts of future events, including with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include, among other things, statements regarding the Company’s: ability to clear all current SEC comments; expectations regarding filing an amended Form 10, including the timeframe therefor and the content therein; and expectations regarding the Company’s plan and ability to satisfy Nasdaq listing requirements. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from the expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the risk that the Company may be unable to list its stock on Nasdaq or maintain compliance with Nasdaq’s continued listing standards; the impact of any changes to the accounting treatment of the Company’s revenue and expenses; the risk of receiving additional comments from the SEC; the competition that the Company faces, which could adversely affect its business, results of operations and financial condition; the risk of rapid technological change, which could cause the Company’s products to become obsolete or cause the Company to become unable to effectively compete; the risk that the Company is unable to successfully market its products to the end users of such products; the risk that the Company may be unable to raise funds to expand its business; changes in applicable laws or regulations; and the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law
